April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Aaron Goodman: Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies
Mar 3, 2024, 17:02

Aaron Goodman: Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies

Aaron Goodman shared an X post by Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, adding:

“Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies (BRAFi, MEKi). This disease is like CML with exquisite and deep responses to single-agent targeted therapy. Just start low (I usually start 25 to 50% dose reduction).”

Quoting Razelle Kurzrock’s post:

“Patients with Erdheim Chester Disease need lowered doses — but they respond.”

Source: Aaron Goodman/X and Razelle Kurzrock/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.